# Robot-Assisted Hysterectomy Provides Higher Sentinel Node Detection and Lower Conversion Rates Compared to Laparoscopy in Endometrial Cancer

**Authors:** Balázs Lintner, Zsófia Havrán, Gabriella Vajda, Lotti Lőczi, Marianna Török, Petra Merkely, Ferenc Bánhidy, Emese Keszthelyi, Richárd Tóth, Márton Keszthelyi

PMC · DOI: 10.3390/life16020244 · 2026-02-02

## TL;DR

Robot-assisted hysterectomy improves sentinel node detection and reduces conversion to open surgery compared to traditional laparoscopy in early-stage endometrial cancer.

## Contribution

Demonstrates real-world clinical advantages of robot-assisted hysterectomy over conventional laparoscopy in endometrial cancer surgery.

## Key findings

- Robot-assisted hysterectomy had a 98% sentinel lymph node detection rate versus 90.2% for laparoscopy.
- Conversion to laparotomy occurred in 0% of robot-assisted cases versus 11.5% of laparoscopic cases.
- Operative time and key pathological outcomes were comparable between the two techniques.

## Abstract

Background: Minimally invasive hysterectomy with sentinel lymph node (SLN) mapping is standard for early-stage endometrial cancer, but comparative real-world data on robot-assisted (RAH) versus conventional laparoscopy (TLH) remain limited. This study aimed to compare the two techniques in a real-world clinical setting. Methods: We retrospectively reviewed medical records of 140 patients with FIGO stage I endometrial cancer who underwent RAH or TLH at Semmelweis University between January 2022 and December 2024. We analyzed patient demographics, sentinel lymph node (SLN) detection rates, conversion rates, operative time, pathological characteristics. Results: Baseline demographic and oncologic characteristics were comparable. SLN detection was significantly higher in the RAH group compared to TLH (98% vs. 90.2%, p = 0.04). Conversion to laparotomy occurred in 0% of RAH cases versus 11.5% of TLH cases (p = 0.0024). Conclusions: In a standardized ICG-guided SLN mapping setting, RAH achieved higher SLN detection and markedly lower conversion rates than TLH, without differences in operative time or key pathological parameters.

## Linked entities

- **Diseases:** endometrial cancer (MONDO:0002447)

## Full-text entities

- **Genes:** SLN (sarcolipin) [NCBI Gene 6588]
- **Diseases:** gynecological malignancies (MESH:D005833), nodal (MESH:D013611), metastases (MESH:D009362), Endometrial Cancer (MESH:D016889), deaths (MESH:D003643), adhesions (MESH:D000267), III (MESH:C537189), hypertension (MESH:D006973), tremor (MESH:D014202), nerve injury (MESH:D000080902), FIGO stage II (MESH:D062706), oncologic (MESH:D000072716), LVSI (MESH:D009361), fibroids (MESH:D007889), gynecological diseases (MESH:D005831), lymph node metastases (MESH:D008207), lymphedema (MESH:D008209), Cancer (MESH:D009369), FIGO stage I endometrial endometrioid carcinoma (MESH:D018269), diabetes mellitus (MESH:D003920), abscess (MESH:D000038), injury to (MESH:D014947), cervical cancer (MESH:D002583), endometriosis (MESH:D004715), incisional hernia (MESH:D000069290), obese (MESH:D009765), bleeding (MESH:D006470), IB disease (MESH:C562594), TLH (MESH:C535338), I (MESH:D006969), lymphocele (MESH:D008210)
- **Chemicals:** ICG (MESH:D007208), RAH (-), water (MESH:D014867)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12941941/full.md

---
Source: https://tomesphere.com/paper/PMC12941941